The cardiac sarcoplasmic/endoplasmic reticulum calcium ATPase: a potent target for cardiovascular diseases
- PMID: 18665137
- DOI: 10.1038/ncpcardio1301
The cardiac sarcoplasmic/endoplasmic reticulum calcium ATPase: a potent target for cardiovascular diseases
Abstract
The cardiac isoform of the sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA2a) is a calcium ion (Ca(2+)) pump powered by ATP hydrolysis. SERCA2a transfers Ca(2+) from the cytosol of the cardiomyocyte to the lumen of the sarcoplasmic reticulum during muscle relaxation. As such, this transporter has a key role in cardiomyocyte Ca(2+) regulation. In both experimental models and human heart failure, SERCA2a expression is significantly decreased, which leads to abnormal Ca(2+) handling and a deficient contractile state. Following a long line of investigations in isolated cardiac myocytes and small and large animal models, a clinical trial is underway that is restoring SERCA2a expression in patients with heart failure by use of adeno-associated virus type 1. Beyond its role in contractile abnormalities in heart failure, SERCA2a overexpression has beneficial effects in a host of other cardiovascular diseases. Here we describe the mechanism of Ca(2+) regulation by SERCA2a, examine the beneficial effects as well as the failures, risks and complexities associated with SERCA2a overexpression, and discuss the potential of SERCA2a as a target for the treatment of cardiovascular disease.
Similar articles
-
Regulation of sarcoplasmic reticulum Ca2+ ATPase pump expression and its relevance to cardiac muscle physiology and pathology.Cardiovasc Res. 2008 Jan 15;77(2):265-73. doi: 10.1093/cvr/cvm056. Epub 2007 Oct 30. Cardiovasc Res. 2008. PMID: 18006443 Review.
-
Restoration of calcium handling properties of adult cardiac myocytes from hypertrophied hearts.Cell Calcium. 2001 Jul;30(1):59-66. doi: 10.1054/ceca.2001.0213. Cell Calcium. 2001. PMID: 11396988
-
Improving cardiac Ca⁺² transport into the sarcoplasmic reticulum in heart failure: lessons from the ubiquitous SERCA2b Ca⁺² pump.Biochem Soc Trans. 2011 Jun;39(3):781-7. doi: 10.1042/BST0390781. Biochem Soc Trans. 2011. PMID: 21599649
-
[Treatment of chronic heart failure by overexpressing sarcoplasmic reticulum calcium ATPase through gene therapy: an experiment with rats].Zhonghua Yi Xue Za Zhi. 2006 May 9;86(17):1174-8. Zhonghua Yi Xue Za Zhi. 2006. PMID: 16796857 Chinese.
-
Factors controlling the activity of the SERCA2a pump in the normal and failing heart.Biofactors. 2009 Nov-Dec;35(6):484-99. doi: 10.1002/biof.63. Biofactors. 2009. PMID: 19904717 Review.
Cited by
-
Benefit of SERCA2a gene transfer to vascular endothelial and smooth muscle cells: a new aspect in therapy of cardiovascular diseases.Curr Vasc Pharmacol. 2013 Jul;11(4):465-79. doi: 10.2174/1570161111311040010. Curr Vasc Pharmacol. 2013. PMID: 23905641 Free PMC article. Review.
-
Cell-Based and Selected Cell-Free Therapies for Myocardial Infarction: How Do They Compare to the Current Treatment Options?Int J Mol Sci. 2022 Sep 7;23(18):10314. doi: 10.3390/ijms231810314. Int J Mol Sci. 2022. PMID: 36142245 Free PMC article. Review.
-
Blocking phospholamban with VHH intrabodies enhances contractility and relaxation in heart failure.Nat Commun. 2022 May 31;13(1):3018. doi: 10.1038/s41467-022-29703-9. Nat Commun. 2022. PMID: 35641497 Free PMC article.
-
SERCA2a gene transfer prevents intimal proliferation in an organ culture of human internal mammary artery.Gene Ther. 2013 Apr;20(4):396-406. doi: 10.1038/gt.2012.50. Epub 2012 Jul 5. Gene Ther. 2013. PMID: 22763406 Free PMC article.
-
Therapeutic efficacy of AAV1.SERCA2a in monocrotaline-induced pulmonary arterial hypertension.Circulation. 2013 Jul 30;128(5):512-23. doi: 10.1161/CIRCULATIONAHA.113.001585. Epub 2013 Jun 26. Circulation. 2013. PMID: 23804254 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous